Molecular diagnosis of intrahepatic cholangiocarcinoma

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 22, Issue 2, 2015, Pages 114-123

  Haga, Hiroaki ^a   Patel, Tushar ^a  

^a MAYO CLINIC   (United States)

Author keywords

Biliary cancers; Biomarkers; Gene fusions; Gene mutations; Liver cancers

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; MICRORNA;

ARTICLE; BILE DUCT CARCINOMA; CANCER PATIENT; CHOLANGITIS; CHOLESTASIS; CYSTIC DUCT; FUSION GENE; GENE FUSION; GENE MUTATION; GENETIC TRAIT; HUMAN; JAUNDICE; LIVER INJURY; META ANALYSIS; MOLECULAR DIAGNOSIS; PRURITUS; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; INTRAHEPATIC BILE DUCT; METABOLISM; PROCEDURES;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 84921961441     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.156     Document Type: Article

References (106)

1. Patel T,. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2006; 3: 33-42.
2. Shaib YH, Davila JA, McGlynn K, El-Serag HB,. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004; 40: 472-477.
3. Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, et-al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg. 2013; 217: 736-750. e4.
4. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, et-al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007; 5: 1221-1228.
5. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA,. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005; 128: 620-626.
6. Palmer WC, Patel T,. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012; 57: 69-76.
7. Kumagai S, Kurumatani N, Arimoto A, Ichihara G,. Cholangiocarcinoma among offset colour proof-printing workers exposed to 1,2-dichloropropane and/or dichloromethane. Occup Environ Med. 2013; 70: 508-510.
8. Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, Zhang L, et-al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012; 43: 1552-1558.
9. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et-al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012; 17: 72-79.
10. Hsu M, Sasaki M, Igarashi S, Sato Y, Nakanuma Y,. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer. 2013; 119: 1669-1674.
11. Chang YT, Chang MC, Huang KW, Tung CC, Hsu C, Wong JM,. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan. J Gastroenterol Hepatol. 2014; 29: 1119-1125.
12. Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, et-al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013; 32: 3091-3100.
13. Sia D, Tovar V, Moeini A, Llovet JM,. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene. 2013; 32: 4861-4870.
14. Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, et-al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011; 224: 334-343.
15. Grassian AR, Pagliarini R, Chiang DY,. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol. 2014; 30: 295-302.
16. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, Leng N, Pavia-Jimenez A, Wang S, et-al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012; 44: 751-759.
17. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, et-al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013; 45: 1470-1473.
18. Chan-On W, Nairismagi ML, Ong CK, Lim WK, Dima S, Pairojkul C, et-al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013; 45: 1474-1478.
19. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et-al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013; 3: 636-647.
20. Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, et-al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014; 59: 1427-1434.
21. Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, et-al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014; 19: 235-242.
22. Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, et-al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014; 10: e1004135.
23. Gerber DE, Minna JD,. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell. 2010; 18: 548-551.
24. Isa T, Tomita S, Nakachi A, Miyazato H, Shimoji H, Kusano T, et-al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology. 2002; 49: 604-608.
25. Kiba T, Tsuda H, Pairojkul C, Inoue S, Sugimura T, Hirohashi S,. Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Mol Carcinog. 1993; 8: 312-318.
26. Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y, et-al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology. 1995; 109: 1612-1617.
27. Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Kockerling F, Hauss J, et-al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut. 2000; 47: 721-727.
28. Kubicka S, Kuhnel F, Flemming P, Hain B, Kezmic N, Rudolph KL, et-al. K-ras mutations in the bile of patients with primary sclerosing cholangitis. Gut. 2001; 48: 403-408.
29. Jang S, Chun SM, Hong SM, Sung CO, Park H, Kang HJ, et-al. High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases. Mod Pathol. 2014; 27: 731-739.
30. Chang F, Syrjanen S, Syrjanen K,. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol. 1995; 13: 1009-1022.
31. Khan SA, Thomas HC, Toledano MB, Cox IJ, Taylor-Robinson SD,. p53 Mutations in human cholangiocarcinoma: a review. Liver Int. 2005; 25: 704-716.
32. Robertson S, Hyder O, Dodson R, Nayar SK, Poling J, Beierl K, et-al. The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. Hum Pathol. 2013; 44: 2768-2773.
33. Ito T, Sakurai-Yageta M, Goto A, Pairojkul C, Yongvanit P, Murakami Y,. Genomic and transcriptional alterations of cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2014; 21: 380-387.
34. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, et-al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006; 130: 2113-2129.
35. Hummel R, Hussey DJ, Haier J,. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer. 2010; 46: 298-311.
36. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D,. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 2013; 52: 297-303.
37. Chusorn P, Namwat N, Loilome W, Techasen A, Pairojkul C, Khuntikeo N, et-al. Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis. Tumour Biol. 2013; 34: 1579-1588.
38. Thiery JP,. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2: 442-454.
39. Oishi N, Kumar MR, Roessler S, Ji J, Forgues M, Budhu A, et-al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology. 2012; 56: 1792-1803.
40. Li B, Han QQ, Zhu Y, Yu Y, Wang JH, Jiang XQ,. Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. FEBS J. 2012; 279: 2393-2398.
41. Huber MA, Kraut N, Beug H,. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005; 17: 548-558.
42. Korita PV, Wakai T, Ajioka Y, Inoue M, Takamura M, Shirai Y, et-al. Aberrant expression of vimentin correlates with dedifferentiation and poor prognosis in patients with intrahepatic cholangiocarcinoma. Anticancer Res. 2010; 30: 2279-2285.
43. Sudo T, Iwaya T, Nishida N, Sawada G, Takahashi Y, Ishibashi M, et-al. Expression of mesenchymal markers vimentin and fibronectin: the clinical significance in esophageal squamous cell carcinoma. Ann Surg Oncol. 2013; 20 (Suppl 3): S324-335.
44. Gu MJ, Choi JH,. Epithelial-mesenchymal transition phenotypes are associated with patient survival in intrahepatic cholangiocarcinoma. J Clin Pathol. 2014; 67: 229-234.
45. Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, et-al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology. 2009; 49: 491-503.
46. Tian F, Li D, Chen J, Liu W, Cai L, Li J, et-al. Aberrant expression of GATA binding protein 6 correlates with poor prognosis and promotes metastasis in cholangiocarcinoma. Eur J Cancer. 2013; 49: 1771-1780.
47. Tang L, Tan YX, Jiang BG, Pan YF, Li SX, Yang GZ, et-al. The prognostic significance and therapeutic potential of hedgehog signaling in intrahepatic cholangiocellular carcinoma. Clin Cancer Res. 2013; 19: 2014-2024.
48. Sanchez P, Hernandez AM, Stecca B, Kahler AJ, DeGueme AM, Barrett A, et-al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci U S A. 2004; 101: 12561-12566.
49. Fabris L, Cadamuro M, Moserle L, Dziura J, Cong X, Sambado L, et-al. Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology. 2011; 54: 890-899.
50. Nakeeb A, Lipsett PA, Lillemoe KD, Fox-Talbot MK, Coleman J, Cameron JL, et-al. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg. 1996; 171: 147-152; discussion 52-3.
51. Nehls O, Gregor M, Klump B,. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis. 2004; 24: 139-154.
52. Kashihara T, Ohki A, Kobayashi T, Sato T, Nishizawa H, Ogawa K, et-al. Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level. J Gastroenterol. 1998; 33: 447-453.
53. Xu H, Inagaki Y, Tang W, Guo Q, Wang F, Seyama Y, et-al. Elevation of serum KL-6 mucin levels in patients with cholangiocarcinoma. Hepatogastroenterology. 2008; 55: 2000-2004.
54. Leelawat K, Leelawat S, Ratanachu-Ek T, Trubwongchareon S, Wannaprasert J, Tripongkaruna S, et-al. Circulating hTERT mRNA as a tumor marker in cholangiocarcinoma patients. World J Gastroenterol. 2006; 12: 4195-4198.
55. Tolek A, Wongkham C, Proungvitaya S, Silsirivanit A, Roytrakul S, Khuntikeo N, et-al. Serum alpha1beta-glycoprotein and afamin ratio as potential diagnostic and prognostic markers in cholangiocarcinoma. Exp Biol Med (Maywood). 2012; 237: 1142-1149.
56. Bamrungphon W, Prempracha N, Bunchu N, Rangdaeng S, Sandhu T, Srisukho S, et-al. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett. 2007; 247: 301-308.
57. Matsuda A, Kuno A, Kawamoto T, Matsuzaki H, Irimura T, Ikehara Y, et-al. Wisteria floribunda agglutinin-positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma. Hepatology. 2010; 52: 174-182.
58. Matsuda A, Kuno A, Matsuzaki H, Kawamoto T, Shikanai T, Nakanuma Y, et-al. Glycoproteomics-based cancer marker discovery adopting dual enrichment with Wisteria floribunda agglutinin for high specific glyco-diagnosis of cholangiocarcinoma. J Proteomics. 2013; 85: 1-11.
59. Shen J, Wang W, Wu J, Feng B, Chen W, Wang M, et-al. Comparative proteomic profiling of human bile reveals SSP411 as a novel biomarker of cholangiocarcinoma. PLoS ONE. 2012; 7: e47476.
60. Shi HJ, Wu AZ, Santos M, Feng ZM, Huang L, Chen YM, et-al. Cloning and characterization of rat spermatid protein SSP411: a thioredoxin-like protein. J Androl. 2004; 25: 479-493.
61. Shi RY, Yang XR, Shen QJ, Yang LX, Xu Y, Qiu SJ, et-al. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery. Cancer. 2013; 119: 993-1003.
62. Ker CG, Chen JS, Lee KT, Sheen PC, Wu CC,. Assessment of serum and bile levels of CA19-9 and CA125 in cholangitis and bile duct carcinoma. J Gastroenterol Hepatol. 1991; 6: 505-508.
63. Sato Y, Harada K, Sasaki M, Nakanuma Y,. Clinicopathological significance of S100 protein expression in cholangiocarcinoma. J Gastroenterol Hepatol. 2013; 28: 1422-1429.
64. Baraniskin A, Nopel-Dunnebacke S, Schumacher B, Gerges C, Bracht T, Sitek B, et-al. Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Dig Dis Sci. 2014; 59: 1436-1441.
65. Li L, Masica D, Ishida M, Tomuleasa C, Umegaki S, Kalloo AN, et-al. Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology. 2014; 60: 896-907.
66. Patel T,. Extracellular vesicle noncoding RNA: new players in the diagnosis and pathogenesis of cholangiocarcinoma. Hepatology. 2014; 60: 782-784.
67. Yokoyama Y, Nishio H, Ebata T, Igami T, Sugawara G, Nagino M,. Value of indocyanine green clearance of the future liver remnant in predicting outcome after resection for biliary cancer. Br J Surg. 2010; 97: 1260-1268.
68. Patel T,. Cholangiocarcinoma-controversies and challenges. Nat Rev Gastroenterol Hepatol. 2011; 8: 189-200.
69. Ahmadzadehfar H, Biersack HJ, Ezziddin S,. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med. 2010; 40: 105-121.
70. Kopek N, Holt MI, Hansen AT, Hoyer M,. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol. 2010; 94: 47-52.
71. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et-al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362: 1273-1281.
72. Hezel AF, Zhu AX,. Systemic therapy for biliary tract cancers. Oncologist. 2008; 13: 415-423.
73. Endo K, Ashida K, Miyake N, Terada T,. E-cadherin gene mutations in human intrahepatic cholangiocarcinoma. J Pathol. 2001; 193: 310-317.
74. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, et-al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012; 142: 1021-1031.
75. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et-al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013; 144: 829-840.
76. Leone F, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, et-al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res. 2006; 12: 1680-1685.
77. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, et-al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut [Research Support, Non-U.S. Gov't]. 2003; 52: 706-712.
78. Tannapfel A, Weinans L, Geissler F, Schutz A, Katalinic A, Kockerling F, et-al. Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Dig Dis Sci. 2000; 45: 317-324.
79. Leelawat K, Narong S, Wannaprasert J, Ratanashu-ek T,. Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J Gastroenterol. 2010; 16: 4697-4703.
80. Uenishi T, Yamazaki O, Tanaka H, Takemura S, Yamamoto T, Tanaka S, et-al. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2008; 15: 583-589.
81. Enjoji M, Yamaguchi K, Nakamuta M, Nakashima M, Kotoh K, Tanaka M, et-al. Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases. Dig Liver Dis. 2004; 36: 622-627.
82. Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R, et-al. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer. 2004; 101: 1609-1615.
83. Mao X, Chen D, Wu J, Li J, Zhou H, Wu Y, et-al. Differential expression of fascin, E-cadherin and vimentin: proteins associated with survival of cholangiocarcinoma patients. Am J Med Sci. 2013; 346: 261-268.
84. Yao X, Wang X, Wang Z, Dai L, Zhang G, Yan Q, et-al. Clinicopathological and prognostic significance of epithelial mesenchymal transition-related protein expression in intrahepatic cholangiocarcinoma. Onco Targets Ther. 2012; 5: 255-261.
85. Huang Q, Liu L, Liu CH, Shao F, Xie F, Zhang CH, et-al. Expression of Smad7 in cholangiocarcinoma: prognostic significance and implications for tumor metastasis. Asian Pac J Cancer Prev. 2012; 13: 5161-5165.
86. Zhai B, Yan HX, Liu SQ, Chen L, Wu MC, Wang HY,. Reduced expression of P120 catenin in cholangiocarcinoma correlated with tumor clinicopathologic parameters. World J Gastroenterol. 2008; 14: 3739-3744.
87. Zhang C, Bai DS, Huang XY, Shi GM, Ke AW, Yang LX, et-al. Prognostic significance of Capn4 overexpression in intrahepatic cholangiocarcinoma. PLoS ONE. 2013; 8: e54619.
88. Iguchi T, Aishima S, Taketomi A, Nishihara Y, Fujita N, Sanefuji K, et-al. Fascin overexpression is involved in carcinogenesis and prognosis of human intrahepatic cholangiocarcinoma: immunohistochemical and molecular analysis. Hum Pathol. 2009; 40: 174-180.
89. Gu FM, Gao Q, Shi GM, Zhang X, Wang J, Jiang JH, et-al. Intratumoral IL-17(+) cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2012; 19: 2506-2514.
90. Higashi M, Yamada N, Yokoyama S, Kitamoto S, Tabata K, Koriyama C, et-al. Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type. Pathobiology. 2012; 79: 101-106.
91. Wang Z, Zheng T, Wu Q, Wang J, Wu C,. Immunohistochemical analysis of the mTOR pathway in intrahepatic cholangiocarcinoma. Neoplasma. 2012; 59: 137-141.
92. Lee D, Do IG, Choi K, Sung CO, Jang KT, Choi D, et-al. The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. Mod Pathol. 2012; 25: 131-139.
93. Boonjaraspinyo S, Boonmars T, Wu ZL, Loilome W, Sithithaworn P, Nagano I, et-al. Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma. Tumor Biol. 2012; 33: 1785-1802.
94. Huang XY, Ke AW, Shi GM, Ding ZB, Devbhandari RP, Gu FM, et-al. Overexpression of CD151 as an adverse marker for intrahepatic cholangiocarcinoma patients. Cancer. 2010; 116: 5440-5451.
95. Dong LW, Hou YJ, Tan YX, Tang L, Pan YF, Wang M, et-al. Prognostic significance of Beclin 1 in intrahepatic cholangiocellular carcinoma. Autophagy. 2011; 7: 1222-1229.
96. Zhou JX, Li Y, Chen SX, Deng AM,. Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma. J Exp Clin Cancer Res. 2011; 30: 2.
97. Shafizadeh N, Grenert JP, Sahai V, Kakar S,. Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. Hum Pathol. 2010; 41: 485-492.
98. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, et-al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008; 98: 418-425.
99. Utispan K, Thuwajit P, Abiko Y, Charngkaew K, Paupairoj A, Chau-in S, et-al. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer. 2010; 9: 13.
100. Xu Y, Zhu M, Zhang S, Liu H, Li T, Qin C,. Expression and prognostic value of PRL-3 in human intrahepatic cholangiocarcinoma. Pathol Oncol Res. 2010; 16: 169-175.
101. Sato Y, Harada K, Itatsu K, Ikeda H, Kakuda Y, Shimomura S, et-al. Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangiocarcinoma. Am J Pathol. 2010; 177: 141-152.
102. Riener MO, Fritzsche FR, Clavien PA, Pestalozzi BC, Probst-Hensch N, Jochum W, et-al. IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. Hum Pathol. 2009; 40: 1377-1383.
103. Hashimoto N, Yachida S, Okano K, Wakabayashi H, Imaida K, Kurokohchi K, et-al. Immunohistochemically detected expression of p27(Kip1) and Skp2 predicts survival in patients with intrahepatic cholangiocarcinomas. Ann Surg Oncol. 2009; 16: 395-403.
104. Lee SM, Lee KE, Chang HJ, Choi MY, Cho MS, Min SK, et-al. Prognostic significance of CD44s expression in biliary tract cancers. Ann Surg Oncol. 2008; 15: 1155-1160.
105. Karamitopoulou E, Tornillo L, Zlobec I, Cioccari L, Carafa V, Borner M, et-al. Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas. Am J Clin Pathol. 2008; 130: 780-786.
106. Aishima S, Nishihara Y, Iguchi T, Taguchi K, Taketomi A, Maehara Y, et-al. Lymphatic spread is related to VEGF-C expression and D2-40-positive myofibroblasts in intrahepatic cholangiocarcinoma. Modern Pathol. 2008; 21: 256-264.